Review of the Therapeutic Uses of Liraglutide

Clinical Therapeutics

Volumn 33, Issue 7, 2011, Pages 793-811

  Ryan, Gina J ^a   Foster, Karla T ^a   Jobe, Lynetta Johnson ^b  

^a MERCER UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND EASTERN SHORE   (United States)

Author keywords

Exenatide; GLP 1 agonist; Glucagon like peptide 1; Incretin hormones; Liraglutide; NN2211; Type 2 diabetes; Victoza

Indexed keywords

ATORVASTATIN; CALCITONIN; DIGOXIN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCAGON; GRISEOFULVIN; HEMOGLOBIN A1C; INSULIN DETEMIR; INSULIN GLARGINE; LIRAGLUTIDE; LISINOPRIL; METFORMIN; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; TETRAHYDROLIPSTATIN;

ABDOMINAL SUBCUTANEOUS FAT; ACUTE PANCREATITIS; AREA UNDER THE CURVE; ARTICLE; ASIAN; CALCITONIN BLOOD LEVEL; CAUCASIAN; DIARRHEA; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED CANCER; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GLUCAGON BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN TREATMENT; INTRAABDOMINAL FAT; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PANCREATITIS; PATIENT COMPLIANCE; SIPPLE SYNDROME; STOMACH EMPTYING; THYROID ADENOMA; THYROID CARCINOMA; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

EID: 79960264355     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.06.004     Document Type: Review

References (88)

1. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008, 31:596-615. American Diabetes Association.
2. Wild S., Roglic G., Green A., et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
3. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 (UKPDS 34). Lancet 1998, 352:854-865. United Kingdom Prospective Diabetes Study Group.
4. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. United Kingdom Prospective Diabetes Study Group.
5. Patel A., MacMahon S., Chalmers J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
6. DeFronzo R.A. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004, 88:787-835. ix.
7. Hoerger T.J., Segel J.E., Gregg E.W., Saaddine J.B. Is glycemic control improving in U.S. Adults?. Diabetes Care 2008, 31:81-86.
8. Creutzfeldt W., Nauck M. Gut hormones and diabetes mellitus. Diabetes Metab Rev 1992, 8:149-177.
9. Nauck M., Stockmann F., Ebert R., Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986, 29:46-52.
10. Doyle M.E., Egan J.M. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 2007, 113:546-593.
11. Deacon C.F., Nauck M.A., Meier J., et al. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 2000, 85:3575-3581.
12. Meier J.J., Nauck M.A., Kranz D., et al. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 2004, 53:654-662.
13. Brown J.C., Dahl M., Kwauk S., et al. Actions of GIP. Peptides 1981, 2:241-245.
14. Yip R.G., Wolfe M.M. GIP biology and fat metabolism. Life Sci 2000, 66:91-103.
15. Deacon C.F., Nauck M.A., Toft-Nielsen M., et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995, 44:1126-1131.
16. Navarro M., Rodriquez de Fonseca F., Alvarez E., et al. Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. J Neurochem 1996, 67:1982-1991.
17. Shughrue P.J., Lane M.V., Merchenthaler I. Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus. Endocrinology 1996, 137:5159-5162.
18. Zander M., Madsbad S., Madsen J.L., Holst J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002, 359:824-830.
19. Toft-Nielsen M.B., Madsbad S., Holst J.J. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 1999, 22:1137-1143.
20. Drucker D.J. The biology of incretin hormones. Cell Metab 2006, 3:153-165.
21. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
22. Toft-Nielsen M.B., Damholt M.B., Madsbad S., et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001, 86:3717-3723.
23. Vilsbøll T., Krarup T., Madsbad S., Holst J.J. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 2002, 45:1111-1119.
24. Nauck M.A., Heimesaat M.M., Orskov C., et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993, 91:301-307.
25. Jones I.R., Owens D.R., Moody A.J., et al. The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion. Diabetologia 1987, 30:707-712.
26. Elahi D., McAloon-Dyke M., Fukagawa N.K., et al. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept 1994, 51:63-74.
27. Mentlein R., Gallwitz B., Schmidt W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993, 214:829-835.
28. Montanya E., Sesti G. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin Ther 2009, 31:2472-2488.
29. Russell-Jones D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Mol Cell Endocrinol 2009, 297:137-140.
30. Chang A.M., Jakobsen G., Sturis J., et al. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003, 52:1786-1791.
31. Degn K.B., Juhl C.B., Sturis J., et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004, 53:1187-1194.
32. Mari A., Degn K., Brock B., et al. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. Diabetes Care 2007, 30:2032-2033.
33. Marre M., Shaw J., Brandle M., et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009, 26:268-278.
34. Nauck M., Frid A., Hermansen K., et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 2009, 32:84-90.
35. Zinman B., Gerich J., Buse J.B., et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 2009, 32:1224-1230.
36. Flint A., Kapitza C., Hinds-berger C., Zdravkovic M. The once-daily human GLP-1 analogue liraglutide decreases post-prandial hunger and energy intake. Diabetes 2008, 57. 555-P.
37. Buse J.B., Rosenstock J., Sesti G., et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374:39-47.
38. Garber A., Henry R., Ratner R., et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009, 373:473-481.
39. Russell-Jones D., Vaag A., Schmitz O., et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009, 52:2046-2055.
40. Zinman B, Gerich J, Buse J, et al. Effect of the GLP-1 analogue liraglutide on glycaemic control and weight reduction in patients on metformin and rosiglitazone: a randomized double-blind placebo-controlled trial. Paper presented at the 44th European Association of the Study of Diabetes (EASD) Annual Meeting; September 7-11, 2008, Rome, Italy:898.
41. Nauck M.A., Kleine N., Orskov C., et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993, 36:741-744.
42. Jendle J., Nauck M., Matthews D., et al. Liraglutide, a once-daily human GLP-1 analog reduces fat percentage, visceral and subcutaneous adipose tissue and hepatic steotosis compared with glimepiride when added to metformin in subejcts with type 2 diabetes. Diabetes 2008, 57. 106-OR.
43. Liu H., Dear A., Knudsen L., Simpson R. A long-acting GLP-1 analogue attenuates induction of PAI-1 and vascular adhesion molecules. J Endocrinol 2009, 201:59-66.
44. Pettigrew K.A., McKnight A.J., Martin R.J., et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patient with Type 2 diabetes. Diabet Med 2008, 25:1125-1131.
45. Agersø H., Vicini P. Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative. Eur J Pharm Sci 2003, 19:141-150.
46. Elbrond B., Jakobsen G., Larsen S., et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002, 25:1398-1404.
47. Damholt B., Golor G., Wierich W., et al. An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide. J Clin Pharmacol 2006, 46:635-641.
48. Jacobsen L.V., Hindsberger C., Robson R., Zdaravkovic M. Effect of renal impairment on the pharmacokinetics of GLP-1 analogue liraglutide. Br J Clin Pharmacol 2009, 68:898-905.
49. Flint A., Nazzal K., Jagielski P., et al. Influence of hepatic impairment on pharmacokinetics of the long-acting human GLP-1 analogue liraglutide. Diabetes 2007, 56. 545-P.
50. Kapitza C., Klein O., Obach R., et al. Long acting human GLP-1 analogue R1583: safety, pharmacokinetic and pharmcodynamic properties after a single administration in subjects with type 2 diabetes. Diabetes 2008, 57. 506-P.
51. Malm-Erjefält M., Bjørnsdottir I., Vanggaard J., et al. Metabolism and excretion of the once daily human GLP-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos 2010, 38:1944-1953.
52. Madsbad S., Schmitz O., Ranstam J., et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004, 27:1335-1342.
53. Feinglos M.N., Saad M.F., Pi-Sunyer F.X., et al. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with type 2 diabetes. Diabet Med 2005, 22:1016-1023.
54. Bode B.W., Testa M.A., Magwire M., et al. Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes. Diabetes Obes Metab 2010, 12:604-612.
55. Seino Y., Rasmussen M.F., Nishida T., Kaku K. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr Med Res Opin 2010, 26:1013-1022.
56. Nathan D.M. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
57. Pratley R.E., Nauck M., Bailey T., et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010, 375:1447-1456.
58. Fakhoury W.K., Lereun C., Wright D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology 2010, 86:44-57.
59. Yang W., Chen L., Ji Q., et al. Liraglutide vs glimepiride, both added to metformin, in an Asian population with T2D: efficay and safety findings from China, South Korea, and India. Diabetes 2010, 59. 699-P.
60. Kaku K., Rasmussen M.F., Clauson P., Seino Y. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes Obes Metab 2010, 12:341-347.
61. Davies M., Lavalle-Gonzalez F., Storms F., Gomis R. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT LANTUS trial. Diabetes Obes Metab 2008, 10:387-399.
62. Cramer J.A., Mattson R.H., Prevey M.L., et al. How often is medication taken as prescribed?. A novel assessment technique. JAMA 1989, 261:3273-3277.
63. Astrup A., Rossner S., Van Gaal L., et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009, 374:1606-1616.
64. Jendle J., Nauck M.A., Matthews D.R., et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 2009, 11:1163-1172.
65. Thum T., Anker S.D. Liraglutide for weight loss in obese people. Lancet 2010, 375:551-552. author reply 552-553.
66. Russell-Jones D, Sesti G, Garber A, et al. A meta-analyis of weight loss incurred by liraglutide in patients with type 2 diabetes with and without gastrointestinal side-effects. Paper presented at the 45th European Association of the Study of Diabetes (EASD) Annual Meeting; September 29-October 2, 2009, Vienna, Austria:835.
67. Jacobsen L.V., Brondsted L., Vouis J., Zdaravkovic M. A randomized, double-blind, cross-over trial investigating the effect of liraglutide on the absorption of an oral contraceptive drug. Diabetes 2008, 57. 2047-PO.
68. Malm-Erjefält M., Ekblom M., Brondsted L., et al. A randomised, double-blind, cross-over trial investigating the effects of liraglutide on the absorption pharmacokinetics of concomitantly administered oral drugs in healthy subjects. Diabetes 2008, 56. 434-P.
69. Morrow L., Hompesch M., Guthrie H., et al. Coadministration of liraglutide with insulin detemir does not affect the pharmacokinetics of either drug. Diabetes 2010, 59. 653-P.
70. Parks M., Rosebraugh C. Weighing risks and benefits of liraglutide-the FDA's review of a new antidiabetic therapy. N Engl J Med 2010, 362:774-777.
71. Lal G., O'Dorisio T., McDougall R., Weigel R.J. Cancer of the endocrine system. Abeloff's Clinical Oncology 2008, Churchill Livingstone Elsevier, Philidephia. 4th ed. M. Abeloff, J. Armitage, J. Niederhuber (Eds.).
72. FDA briefing materials-liraglutide, April 2, 2009 Food and Drug Administration, Accessed September 6, 2010. http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4422b2-01-FDA.pdf.
73. Buse J.B., Sesti G., Schmidt W.E., et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 2010, 33:1300-1303.
74. Information for healthcare professionals: exenatide (marketed as Byetta)-8/2008 US Food and Drug Administration, Accessed October 18, 2010. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm.
75. Klonoff D.C., Buse J.B., Nielsen L.L., et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008, 24:275-286.
76. Noel R.A., Braun D.K., Patterson R.E., Bloomgren G. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective, cohort study. Diabetes Care 2009, 32:834-838.
77. FDA announces new recommendations on evaluating cardiovascular risk in drugs intended to treat type 2 diabetes, December 17, 2008 US Food and Drug Administration, Accessed September 9, 2010. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116994.htm.
78. Sullivan S.D., Alfonso-Cristancho R., Conner C., et al. Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone. Cardiovasc Diabetol 2009, 8:12.
79. Duckworth W., Abraira C., Moritz T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139.
80. Colagiuri S., Frid A., Zdravkovic M., et al. The once-daily human GLP-1 analog, liraglutide reduces systolic blood pressure in patients with type 2 diabetes. Diabetes 2008, 57. 554-P.
81. Victoza (liraglutide) [prescribing Information] May 2010, Novo Nordisk, Princeton, NJ.
82. Kapitza C, Zdravkovic M, Zijlstra E, et al. Effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide. J Clin Pharmacol. 201l;51:951-955.
83. Red Book 2010: Pharmacy's Fundamental Reference 2010, 805. Thomson Reuters (Healthcare) Inc, PDR Network, Montvale, NJ.
84. Jendle J., Torffvit O., Ridderstr M., et al. Patient willingness-to-pay for liraglutide and glimepiride based on head-to-head clinical trial results. Diabetes 2010, 59. 1312-P.
85. Palmer A.J., Roze S., Valentine W.J., et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004, 20:S5-S26.
86. Rodbard H.W., Jellinger P.S., Davidson J.A., et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009, 15:540-559.
87. Monnier L., Colette C., Dunseath G.J., Owens D.R. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007, 30:263-269.
88. Monnier L., Lapinski H., Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003, 26:881-885.